Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy (opens in a new tab)

news-medical.net · 2026-10-24

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 9Not checkedAdding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.View evidenceHide evidence

As stated42%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 9Not checkedThe vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 9Not checkedThe trial randomly assigned 1,137 adults who had undergone surgery for stage IIB-IV cutaneous melanoma to pembrolizumab plus either intismeran (757 patients) or placebo (380 patients).View evidenceHide evidence

As stated1,137 adults; 757 vs 380

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 9Not checkedAfter a median follow-up of 24.6 months, adding intismeran reduced the risk of recurrence or death (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.45-0.75; p<0.001).View evidenceHide evidence

As statedHR 0.58

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 9Not checkedAt two years, 82.2% of patients receiving the combination were alive without recurrence, compared with 70.0% receiving pembrolizumab alone.View evidenceHide evidence

As stated82.2% vs 70.0%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 9Not checkedThe combination also reduced the risk of distant metastasis or death by 38% (HR 0.62; 95% CI 0.45-0.85; p=0.002), with 88.5% versus 80.2% alive without distant metastasis at two years.View evidenceHide evidence

As stated38%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 7 of 9Not checkedOverall survival data were still immature at this interim analysis, with no statistically significant difference between the groups (HR 0.77; 95% CI 0.45-1.31), and longer follow-up is needed to determine whether the reduction in recurrence translates into a survival benefit.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 8 of 9Not checkedGrade 3 or higher adverse events occurred in 23.6% of patients receiving the combination and 20.3% receiving pembrolizumab alone, and the most common side effects with the combination were fever, injection-site pain, and fatigue.View evidenceHide evidence

As stated23.6% vs 20.3%; fever 52.2% vs 8.2%; injection-site pain 51.0% vs 9.5%; fatigue 38.5% vs 29.7%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 9 of 9Not checkedThe article says this is the first phase 3 study to show that a treatment built from the unique fingerprint of a patient's own tumor can reduce the risk of recurrence or death from cancer.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

Annals of Oncology · 2024 · Crossref

Source (opens in a new tab)
Candidate

Abstract CT224: mRNA-4157, a personalized cancer vaccine, in combination with pembrolizumab, demonstrates trend for improved recurrence free survival compared to pembrolizumab alone in adjuvant melanoma patients across tumor mutational burden subgroups

Cancer Research · 2023 · Crossref

Source (opens in a new tab)

Explore all search results